Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $35.5 million.

  • Immunome's Total Liabilities fell 1556.01% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.5 million, marking a year-over-year decrease of 1556.01%. This contributed to the annual value of $59.1 million for FY2024, which is 10614.14% up from last year.
  • As of Q3 2025, Immunome's Total Liabilities stood at $35.5 million, which was down 1556.01% from $27.0 million recorded in Q2 2025.
  • Immunome's Total Liabilities' 5-year high stood at $87.1 million during Q3 2023, with a 5-year trough of $27.0 million in Q2 2025.
  • Moreover, its 3-year median value for Total Liabilities was $35.5 million (2025), whereas its average is $41.6 million.
  • Data for Immunome's Total Liabilities shows a peak YoY increase of 10614.14% (in 2024) and a maximum YoY decrease of 5178.04% (in 2024) over the last 5 years.
  • Over the past 3 years, Immunome's Total Liabilities (Quarter) stood at $28.7 million in 2023, then skyrocketed by 106.14% to $59.1 million in 2024, then plummeted by 39.98% to $35.5 million in 2025.
  • Its Total Liabilities was $35.5 million in Q3 2025, compared to $27.0 million in Q2 2025 and $35.6 million in Q1 2025.